Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.

MLA

Evangelist, Makenzi Colleen, et al. “Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results from the MYLUNG Pragmatic Study.” Journal of Clinical Oncology, vol. 41, June 2023, p. 9109. EBSCOhost, https://doi.org/10.1200/JCO.2023.41.16_suppl.9109.

APA

Evangelist, M. C., Butrynski, J. E., Paschold, J. C., Ward, P. J., Spira, A. I., Ali, K., Espirito, J. L., Hakimian, D., Jotte, R. M., Koselke, B., Larson, T., Meshad, M. W., Neubauer, M. A., Ogden, K., Owera, R., Richards, D. A., Robert, N. J., Walberg, J. M., Wang, Y., & Coleman, R. L. (2023). Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. Journal of Clinical Oncology, 41, 9109. https://doi.org/10.1200/JCO.2023.41.16_suppl.9109

Chicago

Evangelist, Makenzi Colleen, James Edward Butrynski, John C. Paschold, Patrick J. Ward, Alexander I. Spira, Kashif Ali, Janet L. Espirito, et al. 2023. “Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results from the MYLUNG Pragmatic Study.” Journal of Clinical Oncology 41 (June): 9109. doi:10.1200/JCO.2023.41.16_suppl.9109.